Multiple Sclerosis, the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. The r ...

On the basis of their well-established efficacy and tolerability profiles, IFNβ formulations and glatiramer acetate have been the mainstay of initial treatment for multiple sclerosis (MS) patients.

People with multiple sclerosis (MS) often face higher unemployment rates. Understanding the challenges and available support can help you navigate employment and financial stability. Many people ...

The objective of this investigation was to examine treatment persistence with glatiramer acetate (GA) relative to available disease-modifying therapies (DMT) for multiple sclerosis (MS ...

The National Cancer Institute estimates that 36,110 people in 2025 will be newly affected by multiple myeloma, the second most common blood cancer. Provided by University of Miami Leonard M ...